Stoke Net Income Per Share from 2010 to 2026

STOK Stock  USD 31.63  0.77  2.38%   
Stoke Therapeutics Net Loss yearly trend continues to be quite stable with very little volatility. The value of Net Loss is projected to decrease to -1.99. From the period between 2010 and 2026, Stoke Therapeutics, Net Loss regression line of its data series had sample variance of  0.88 and sample variance of  0.88. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(1.89)
Current Value
(1.99)
Quarterly Volatility
0.93919012
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Stoke Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Stoke Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 15.3 M, Interest Income of 131.1 K or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 26.26, Dividend Yield of 0.0 or PTB Ratio of 2.46. Stoke financial statements analysis is a perfect complement when working with Stoke Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Stoke Stock
Check out the analysis of Stoke Therapeutics Correlation against competitors.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.
Historical Net Income Per Share data for Stoke Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Stoke Therapeutics represents a compelling investment opportunity.

Latest Stoke Therapeutics' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Stoke Therapeutics over the last few years. It is Stoke Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Stoke Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Stoke Net Income Per Share Regression Statistics

Arithmetic Mean(1.10)
Coefficient Of Variation(85.73)
Mean Deviation0.87
Median(0.53)
Standard Deviation0.94
Sample Variance0.88
Range2.3619
R-Value(0.85)
Mean Square Error0.26
R-Squared0.73
Significance0.000013
Slope(0.16)
Total Sum of Squares14.11

Stoke Net Income Per Share History

2026 -1.99
2025 -1.89
2024 -1.65
2023 -2.38
2022 -2.6
2021 -2.34
2020 -1.56

About Stoke Therapeutics Financial Statements

Stoke Therapeutics investors utilize fundamental indicators, such as Net Income Per Share, to predict how Stoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss(1.89)(1.99)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Stoke Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stoke Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Stoke Therapeutics Stock:
Check out the analysis of Stoke Therapeutics Correlation against competitors.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Stoke Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
0.68
Revenue Per Share
3.547
Quarterly Revenue Growth
1.172
Return On Assets
0.052
Return On Equity
0.1502
Investors evaluate Stoke Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Stoke Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Stoke Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Stoke Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.